# A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

> **NCT03289962** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 272 (actual)

## Conditions studied

- Melanoma
- Non-Small Cell Lung Cancer
- Bladder Cancer
- Colorectal Cancer
- Triple Negative Breast Cancer
- Renal Cancer
- Head and Neck Cancer
- Other Solid Cancers

## Interventions

- **DRUG:** Autogene cevumeran
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03289962
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-21
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2025-07-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03289962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03289962, "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03289962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*